Behavioral
Dothan Pediatric Clinic, P. A.
Dothan Pediatric Clinic, P. A. was paid $56.79M by Medicaid between Jan 2018 and Dec 2024, across 103 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 33% of everything it billed.
33Billing provider infoDOTHAN PEDIATRIC CLINIC, P. A.
DOTHAN, AL 36303
DOTHAN, AL 36303
33aNPI1376508788assigned 04/19/2006
33bProvider typeClinical Psychologist
28Total paid$56.79M
24GClaims1,441,797
24DCodes billed103
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Psychologist providers in Alabama
Rank by total paid#1 of 25
Median peer was paid$107K
This provider vs. median533×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 156,520 | $5.93M | |
| 2019 | 205,884 | $7.87M | |
| 2020 | 164,027 | $6.44M | |
| 2021 | 238,235 | $9.40M | |
| 2022 | 250,836 | $9.96M | |
| 2023 | 236,773 | $9.06M | |
| 2024incomplete | 189,522 | $8.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33% | 312,760 | 288,969 | $18.61M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 21% | 131,679 | 123,634 | $11.97M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.6% | 46,044 | 45,186 | $3.17M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 5.0% | 39,984 | 39,206 | $2.84M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.2% | 36,104 | 35,470 | $2.38M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.8% | 24,543 | 24,042 | $1.60M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.8% | 51,831 | 49,674 | $1.05M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 23,112 | 22,312 | $949K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.6% | 7,140 | 6,674 | $912K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 1.5% | 5,424 | 5,197 | $869K |
| 90698 | 1.5% | 33,492 | 32,916 | $837K | |
| 87430 | 1.4% | 64,720 | 62,459 | $806K |
91 more codes
| 90670 | 1.4% | 25,659 | $791K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.1% | 11,685 | $633K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.0% | 1,569 | $578K |
| 87070 | <1% | 52,923 | $541K | |
| 92552 | <1% | 82,421 | $510K | |
| 90680 | <1% | 20,589 | $505K | |
| 90651 | <1% | 7,949 | $483K | |
| D1206 | Topical application of fluoride varnish | <1% | 20,767 | $468K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 45,226 | $405K |
| 90716 | <1% | 11,005 | $381K | |
| 99245 | <1% | 1,866 | $371K | |
| 99173 | <1% | 88,127 | $368K | |
| 95782 | <1% | 745 | $363K | |
| 90461 | <1% | 5,388 | $337K | |
| 90688 | <1% | 18,380 | $335K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 9,239 | $291K |
| 90707 | <1% | 10,910 | $288K | |
| 90671 | <1% | 7,354 | $269K | |
| 90633 | <1% | 13,138 | $261K | |
| 90744 | <1% | 12,478 | $238K | |
| 94010 | <1% | 7,557 | $155K | |
| 90621 | <1% | 2,734 | $151K | |
| 90734 | <1% | 3,237 | $137K | |
| 90687 | <1% | 7,675 | $134K | |
| 83655 | <1% | 9,184 | $127K | |
| 96127 | <1% | 37,019 | $116K | |
| 90619 | <1% | 2,257 | $106K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 10,621 | $100K |
| 80061 | Lipid panel | <1% | 7,740 | $97K |
| 99051 | <1% | 36,847 | $96K | |
| 90756 | <1% | 4,237 | $85K | |
| 99177 | <1% | 4,545 | $70K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,359 | $69K |
| 99461 | <1% | 769 | $67K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 2,366 | $64K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 315 | $61K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,519 | $58K |
| 81003 | <1% | 19,683 | $52K | |
| 95811 | <1% | 113 | $52K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 878 | $51K |
| 90696 | <1% | 1,709 | $50K | |
| 90661 | <1% | 2,359 | $48K | |
| 87634 | <1% | 953 | $44K | |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 1,770 | $41K |
| 90715 | <1% | 1,319 | $32K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,012 | $32K |
| 99188 | <1% | 1,660 | $30K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,918 | $30K |
| 74018 | <1% | 1,595 | $27K | |
| 99243 | <1% | 244 | $26K | |
| 82947 | <1% | 7,319 | $26K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,132 | $22K |
| 94664 | <1% | 1,851 | $15K | |
| 36416 | <1% | 5,175 | $12K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 102 | $12K |
| 90381 | <1% | 42 | $9K | |
| 88720 | <1% | 1,748 | $8K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 861 | $8K |
| 0071A | <1% | 227 | $7K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 261 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 810 | $7K |
| 90632 | <1% | 83 | $4K | |
| 0072A | <1% | 107 | $4K | |
| 96161 | <1% | 1,365 | $4K | |
| 46505 | <1% | 29 | $4K | |
| 87807 | <1% | 327 | $3K | |
| 94060 | <1% | 88 | $3K | |
| 99384 | <1% | 39 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 17 | $2K |
| 98966 | <1% | 204 | $2K | |
| 81001 | <1% | 476 | $2K | |
| 82465 | <1% | 366 | $2K | |
| 85651 | <1% | 377 | $1K | |
| 0001A | <1% | 40 | $1K | |
| 69210 | <1% | 34 | $970.56 | |
| 0012A | <1% | 19 | $760.00 | |
| 96380 | <1% | 49 | $754.48 | |
| 0011A | <1% | 16 | $600.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 47 | $552.73 |
| 90380 | <1% | 24 | $474.96 | |
| 70360 | <1% | 26 | $432.00 | |
| 81025 | <1% | 149 | $418.89 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 37 | $380.00 |
| 74019 | <1% | 12 | $256.64 | |
| 98967 | <1% | 12 | $209.33 | |
| 77072 | <1% | 13 | $184.27 | |
| 82962 | <1% | 26 | $75.00 | |
| 91300 | 0% | 152 | $0.00 | |
| 95251 | 0% | 123 | $0.00 | |
| 91307 | 0% | 521 | $0.00 | |
| 91301 | 0% | 46 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTOLAR, GINA (INSURANCE & COLLECTION SUPERVISOR)